Supernus Pharmaceuticals Inc (NASDAQ: SUPN) stock enjoyed a major increase of 14.5% on 8/7/24. The shares closed at $31.92. Moreover, trading volume in this advance was exceptionally high at 299% of normal. The stock has risen 5.4% during the last week and has performed in line with the market over the last nine months.
Current PriceTarget Research Rating
SUPN’s future returns on capital are forecasted to exceed the cost of capital. Accordingly, the company is expected to continue to be a Value Builder.
Supernus Pharmaceuticals has a current Value Trend Rating of D (Negative). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing highly consistent signals. Supernus Pharmaceuticals has a neutral Appreciation Score of 46 and a neutral Power Rating of 58, triggering the Negative Value Trend Rating.
Rating Review
In light of this very positive price change we are reviewing our current Overall Rating of D. This review will be completed in the next several days.
Be the first to comment